Login / Signup

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Gemma BrueraSilvia MassaceseFrancesco PepeUmberto MalapelleAntonella Dal MasEugenio CiaccoGiuseppe CalvisiGiancarlo TronconeMaurizio SimmacoEnrico Ricevuto
Published in: Therapeutic advances in medical oncology (2019)
The trial was registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2009-016793-32.
Keyphrases